Drug intelligence / Profile preview

Maxicold

Development stage
Unknown
Lead developer
OTCPharm
Modality
Small Molecules
Administration
Oral
01

Overview

Maxicold (often misspelled as Maxicom in some contexts) is a multi-component over-the-counter (OTC) medication developed and marketed by OTCPharm for the symptomatic relief of the common cold, influenza, and other acute respiratory viral infections (ARVI). The standard formulation is typically a powder for oral solution containing paracetamol (analgesic and antipyretic), phenylephrine hydrochloride (nasal decongestant), pheniramine maleate (antihistamine), and ascorbic acid (Vitamin C). Paracetamol reduces fever and pain by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine acts as an alpha-1 adrenergic receptor agonist to reduce nasal mucosal edema and congestion. Pheniramine is an H1-receptor antagonist that alleviates allergic-like symptoms such as sneezing and rhinorrhea. Ascorbic acid is included to support immune function during infection. The brand also encompasses other formulations, including throat sprays and pediatric suspensions.

Brand names
MaxicoldМаксиколдMaxicomМаксиком
Other names
Maxicold RinMaxicold Lor
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Maxicold.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxicold.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call